Spexis AG
Spexis is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer. They aim to target difficult-to-drug structures with their macrocyclic technology platform, delivering transformative product candidates to benefit patients and create value for stakeholders. The company was created through a merger and is seeking partners for its programs in rare disease and oncology.
Industries
Nr. of Employees
small (1-50)
Spexis AG
Products
Inhaled murepavadin (inhaled antibiotic candidate)
Inhaled antibiotic candidate targeting Pseudomonas aeruginosa for treatment of chronic infections in cystic fibrosis and non-CF bronchiectasis; reported Phase 1 clinical activity and ongoing development.
Balixafortide (CXCR4 inhibitor)
Macrocyclic CXCR4 antagonist investigated in multiple clinical trials (over 400 subjects) for oncology indications and stem cell mobilization; studied as single agent and in combination.
Lonodelestat (neutrophil elastase inhibitor) — out-licensed
Neutrophil elastase inhibitor program for cystic fibrosis, alpha-1 antitrypsin deficiency and primary ciliary dyskinesia that has been out-licensed to an external company for further development.
ColiFin (inhaled therapeutic referenced in corporate overview)
Inhaled therapeutic referenced as an advanced clinical candidate for cystic fibrosis and described as having received marketing authorization in Europe (as described in corporate overview).
Inhaled murepavadin (inhaled antibiotic candidate)
Inhaled antibiotic candidate targeting Pseudomonas aeruginosa for treatment of chronic infections in cystic fibrosis and non-CF bronchiectasis; reported Phase 1 clinical activity and ongoing development.
Balixafortide (CXCR4 inhibitor)
Macrocyclic CXCR4 antagonist investigated in multiple clinical trials (over 400 subjects) for oncology indications and stem cell mobilization; studied as single agent and in combination.
Lonodelestat (neutrophil elastase inhibitor) — out-licensed
Neutrophil elastase inhibitor program for cystic fibrosis, alpha-1 antitrypsin deficiency and primary ciliary dyskinesia that has been out-licensed to an external company for further development.
ColiFin (inhaled therapeutic referenced in corporate overview)
Inhaled therapeutic referenced as an advanced clinical candidate for cystic fibrosis and described as having received marketing authorization in Europe (as described in corporate overview).
Services
Partnering and licensing for drug development
Strategic collaboration and licensing of development and commercialization rights for preclinical and clinical-stage therapeutic programs.
Partnering and licensing for drug development
Strategic collaboration and licensing of development and commercialization rights for preclinical and clinical-stage therapeutic programs.
Expertise Areas
- Macrocycle drug discovery
- Inhaled drug development for respiratory indications
- Anti-infective and Gram-negative antibiotic development
- Oncology drug development (including CXCR4-directed programs)
Key Technologies
- Macrocyclic therapeutics
- Outer membrane protein-targeting antibiotics
- Inhalation drug delivery and formulation
- CXCR4 antagonists